Extended Data Table 1.

Clinical data for 14 patients with endometrium carcinoma enrolled in NP137 trial

a, Median progression-free survival (mPFS) and overall survival (mOS) are presented with their 95% confidence interval (95% CI). Best overall response is also presented. N: number of patients. b, Table resuming target lesion size evolution and non-target lesions from baseline to 6 months of patient no. 02.004. PR indicates partial response, SD indicates stable disease as per RECIST V1.1. PR was identified both by investigator review and by centralized review.